Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia

Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Shionogi & Co., Ltd. (“Shionogi”) today announce that QUVIVIQ™ (daridorexant) 25 and 50 mg has been launched and is now available in Japan as a new treatment for adults with insomnia.

QUVIVIQ™ is an oral Dual Orexin Receptor Antagonist (DORA) for the treatment of insomnia that selectively binds to receptors of the wake-promoting neuropeptide orexin (OX1R and OX2R), inhibiting excessive wakefulness and facilitating the transition to sleep.

Nxera Pharma Japan Co., Ltd. (a wholly owned subsidiary of Nxera Pharma) is the approval holder and will be responsible in part for provision of drug product. Shionogi will be solely responsible for distribution and sales activities for QUVIVIQ™ in Japan under the commercial partnership agreement with Nxera Pharma announced on 1 October 2024.

For Nxera, reaching this important milestone highlights its ability to develop novel therapeutics for patients in Japan and reinforces its ambition to be a partner of choice for companies looking to develop and commercialize new therapeutics for the Japanese market.

As a new pillar, Shionogi is focusing on the 'QOL disease area,' which is less affected by trends. Starting with the launch of QUVIVIQ™, Shionogi is working to strengthen the 'QOL disease area' as a solid pillar.

Together, Nxera and Shionogi are committed to deliver QUVIVIQ™ as quickly as possible as a product that has the potential to meet the needs of insomnia patients for a long time to come.